Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study-Reference-Cited by-同舟云学术

Uracil/ftorafur/leucovorin combined with irinotecan (TEGAFIRI) or oxaliplatin (TEGAFOX) as first-line treatment for metastatic colorectal cancer patients: results of randomised phase II study

Published:2007-01-23 Issue:3 Volume:96 Page:439-444
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Bajetta E, ,Di Bartolomeo M,Buzzoni R,Mariani L,Zilembo N,Ferrario E,Lo Vullo S,Aitini E,Isa L,Barone C,Jacobelli S,Recaldin E,Pinotti G,Iop A

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/6603493.pdf

Reference25 articles.

1. Alonso V, Escudero P, Zorrilla M, Isla MD, herrero A, Mayordomo JI, Martines-Trufero J, Saenz A, tres A, Anton A (2001) Phase I trial of weeekly irinotecan combined with UFT as second-line treatment for advanced colorectal cancer. Eur J Cancer 37: 2385–2391

2. Bajetta E, Di Bartolomeo M, Mariani L, Cassata A, Artale S, Frustaci S, Pinotti G, Bonetti A, Carreca I, Biasco G, Bonaglia L, Marini G, Iannelli A, Cortinovis D, Ferrario E, Beretta E, Lambiase A, Buzzoni R (2004) Randomized multicenter phase II trial of two different schedules of irinotecan combined to capecitabine as first line treatment in metastatic colorectal cancer. Cancer 100: 279–287

3. Bennouna J, Perrier H, Paillot B, Priou F (2006) A phase II study of oral uracil/ftorafur (UFT) plus leucovorin combinae with oxaliplatin(TEGAFOX) as first-line treatment in patients with metastatic colorectal cancer. Br J Cancer 94: 69–73

4. Carmichael J, Popiela T, Radstone D, Falk S, Borner M, Oza A, Skovsgaard T, Munier S, Martin C (2002) Randomized comparative study of tegafur/uracil and oral leucovorin vs parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 20: 3617–3627

5. Colucci G, Gebbia V, Paletti GC, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L, Borsellino N, Misino A, Romito S, Durini E, Cordio S, Di Seri M, Lopez M, Maiello E, Montemurro S, Cramarossa A, Lorusso V, Di Bisceglie M, Chiarenza M, Valerio MR, Guida T, Leonardi V, Pisconti S, Rosati G, Carrozza F, Nettis G, Valdesi M, Filippelli G, Fortunato S, Mancarella S, Brunetti C, Gruppo Oncologico Dell'Italia Meridionale (2005) Phase III randomized trial of FOLFIRI vs FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). J Clin Oncol 23: 4866–4875

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparison of irinotecan and oxaliplatin as the first-line therapies for metastatic colorectal cancer: a meta-analysis;BMC Cancer;2021-02-04

2. Colorectal Cancer Chemotherapy during COVID-19 Pandemic;Indian Journal of Medical and Paediatric Oncology;2020-03

3. A phase I study of oral UFT/leucovorin and irinotecan, plus radiation for locally recurrent rectal cancer;Journal of the Anus, Rectum and Colon;2017-04-27

4. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer - results from a non-interventional observation study;BMC Cancer;2016-02-10

5. TEGAFIRI is an effective alternative regimen for the management of recurrent or metastatic colorectal cancer;Oncology Letters;2015-01-07